[go: up one dir, main page]

WO2005077046A3 - Composition et procede pour le traitement de la mastite - Google Patents

Composition et procede pour le traitement de la mastite Download PDF

Info

Publication number
WO2005077046A3
WO2005077046A3 PCT/US2005/004048 US2005004048W WO2005077046A3 WO 2005077046 A3 WO2005077046 A3 WO 2005077046A3 US 2005004048 W US2005004048 W US 2005004048W WO 2005077046 A3 WO2005077046 A3 WO 2005077046A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
treating mastitis
lytic
specific
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/004048
Other languages
English (en)
Other versions
WO2005077046A2 (fr
Inventor
Lawrence Loomis
Vincent Fischetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of WO2005077046A2 publication Critical patent/WO2005077046A2/fr
Anticipated expiration legal-status Critical
Priority to US11/510,805 priority Critical patent/US20070077235A1/en
Publication of WO2005077046A3 publication Critical patent/WO2005077046A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition et un procédé pour le traitement de la mastite, ce traitement consistant à utiliser une quantité efficace d'au moins un agent lytique spécifique de la bactérie provoquant la maladie. L'enzyme lytique est génétiquement codée par un bactériophage qui peut être spécifique de ladite bactérie. Cette enzyme peut être au moins une protéine ou des peptides lytiques sous forme naturelle ou modifiée.
PCT/US2005/004048 2004-01-16 2005-02-10 Composition et procede pour le traitement de la mastite Ceased WO2005077046A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/510,805 US20070077235A1 (en) 2004-01-16 2006-08-14 Composition and method of treating mastitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54365104P 2004-02-12 2004-02-12
US60/543,651 2004-02-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/510,805 Continuation US20070077235A1 (en) 2004-01-16 2006-08-14 Composition and method of treating mastitis

Publications (2)

Publication Number Publication Date
WO2005077046A2 WO2005077046A2 (fr) 2005-08-25
WO2005077046A3 true WO2005077046A3 (fr) 2009-03-26

Family

ID=34860445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004048 Ceased WO2005077046A2 (fr) 2004-01-16 2005-02-10 Composition et procede pour le traitement de la mastite

Country Status (1)

Country Link
WO (1) WO2005077046A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106951A1 (fr) 2006-03-23 2007-09-27 Agriculture Victoria Services Pty Limited Protéine antimicrobienne
AU2007298511B2 (en) * 2006-07-10 2013-03-21 Advanced Enzyme Technologies Limited Compositions for prevention and treatment of mastitis and metritis
US8956628B2 (en) 2007-12-13 2015-02-17 Zoetis Products Llc Bacteriophage preparations and method of use thereof
US20110209228A1 (en) * 2008-03-13 2011-08-25 Benjamin Cocks Method of treatment using antimicrobial composition
CN116640755B (zh) * 2023-07-21 2023-10-20 临沂大学 一种链球菌前噬菌体裂解酶lys1519及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US6238661B1 (en) * 1997-10-31 2001-05-29 New Horizons Diagnostics Corp. Use of bacterial phage associated lysing enzymes for treating various illnesses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US6238661B1 (en) * 1997-10-31 2001-05-29 New Horizons Diagnostics Corp. Use of bacterial phage associated lysing enzymes for treating various illnesses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KERR ET AL.: "Mammary expression of new genes to combat mastitis.", J ANIM SCI., vol. 81, no. 3, 2003, pages 38 - 47 *
LOEFFLER ET AL.: "Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.", SCIENCE., vol. 294, no. 5549, 7 December 2001 (2001-12-07), pages 2170 - 2172, XP002392510, DOI: doi:10.1126/science.1066869 *

Also Published As

Publication number Publication date
WO2005077046A2 (fr) 2005-08-25

Similar Documents

Publication Publication Date Title
WO2007016097A3 (fr) Valvule veineuse prothétique implantable
GEP20166454B (en) Sclerostin binding agents
MXPA05010830A (es) Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
WO2007120626A3 (fr) Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
WO2006068729A3 (fr) Procedes et compositions pour ameliorer l'absorption de fer
WO2004027020A3 (fr) Identification d'une enzyme lytique associee a un phage visant a detecter et a eliminer rapidement et specifiquement bacillus anthracis
WO2009118662A3 (fr) Compositions et méthodes de traitement de la perte osseuse
EP2428222A3 (fr) Combinaisons de peptide de vaccin contre l'allergie aux chats
SG161247A1 (en) Variant forms of urate oxidase and use thereof
WO2004064732A3 (fr) Utilisation de proteines lytiques associees a des bacteriophages pour la prevention et le traitement d'infections bacteriennes chez l'etre humain, les animaux et les volailles
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
WO2008143705A3 (fr) Procédés et compositions pour l'inactivation rapide de protéines
WO2006059247A8 (fr) Anti-infectieux a base de proteine isd pour une infection a staphylococcus aureus
ATE345354T1 (de) Methode zur identifizierung von helicobacter antigenen
WO2007024628A3 (fr) Lysines de mutant plygbs
WO2006100679A3 (fr) Anticorps de recombinaison diriges contre la transglutaminase humaine de type ii et utilisations de ces anticorps
WO2005077046A3 (fr) Composition et procede pour le traitement de la mastite
SE0401631L (sv) Ny sammansättning
WO2006135493A3 (fr) Composition utilisee dans la cicatrisation de plaies et utilisation correspondante
WO2021216876A3 (fr) Anticorps dirigés contre la protéine de spicule de coronavirus et leurs procédés d'utilisation
WO2005092924A8 (fr) Rab9a, rab11a et leurs modulateurs lies a une maladie infectieuse
WO2004009029A3 (fr) Compositions et procedes de traitement et de prevention d'infections
WO2004000222A3 (fr) Utilisation de proteines lytiques associees a des bacteriophages pour traiter des caries dentaires bacteriennes
WO2007061924A3 (fr) Methodes de traitement de defauts de cartilage
WO2005077356A3 (fr) Composition et procede destine aux etats affectant les cartilages

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11510805

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 11510805

Country of ref document: US

122 Ep: pct application non-entry in european phase